Stefan Faderl

TL;DR: VNP40101M had significant antileukemic activity and minimal extramedullary toxicity in patients with refractory or relapsed leukemias or poor-risk myelodysplastic syndromes and was selected as the recommended Phase II dose.

TL;DR: In this article, the authors analyzed the outcome of 435 patients with early chronic-phase, Philadelphia chromosome-positive CML treated with imatinib (n = 281), nilotinib(n = 78), and dasatinib-n = 76 using definitions of PFS and EFS used in the International Randomized Study of Interferon Versus STI571 (IRIS), Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENEST-nd), Dasatinib Versus Imatinib Study in Treatment-Na

TL;DR: The incidence of EMD in 263 patients with APL who were treated at this institution from January 1990 to May 2008 is low; the molecular status did not predict EMD; four patients had a negative PCR for the PML-RARA transcripts prior to relapse with EMD.

TL;DR: Questions remain regarding the role of the microenvironment, which may or may not facilitate the survival and proliferation of EML, and the implications of these interactions with regard to minimal residual disease, tumor cell quiescence and relapse, and prospective studies of detection and characterization of E ML in patients with AML are warranted.

TL;DR: It remains to be determined whether routine CNS prophylaxis would improve DFS, and patients receiving high-dose cytarabine and those who did not had similar rates of CNS involvement.